Eosin 1% solution
Requires a prescription from a doctor or prescriber
Group of bromo derivatives of fluorescein used as red dye
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(4)
OSNA for colon cancer staging (MIB77)
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
Paige Prostate for prostate cancer (MIB280)
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · 1950–2026
Showing the 50 most relevant studies, sorted by most relevant.
John K. C. Chan
International Journal of Surgical Pathology, 2014
- Coloring Agents
- Eosine Yellowish-(YS)
- Hematoxylin
J. Bancroft, C. Layton
Bancroft's Theory and Practice of Histological Techniques, 2019
Mark R. Wick
Seminars in Diagnostic Pathology, 2019
- Eosine Yellowish-(YS)
- Hematoxylin
- Quality Assurance, Health Care
Saman Farahmand, Aileen I. Fernandez, Fahad Ahmed, et al.
Modern Pathology, 2021
- Trastuzumab
- Antineoplastic Agents, Immunological
- Breast Neoplasms
A. Fischer, K. Jacobson, Jack Rose, et al.
CSH protocols, 2008
Ada T. Feldman, Delia Wolfe
Methods in molecular biology, 2014
- Bone Marrow Cells
- Eosine Yellowish-(YS)
- Hematoxylin
Robert D. Cardiff, Claramae H. Miller, Robert J. Munn
Cold Spring Harbor Protocols, 2014
- Eosine Yellowish-(YS)
- Hematoxylin
- Histocytochemistry
C. A. Parker, C. G. Hatchard
Transactions of the Faraday Society, 1961
Lars Björndahl
Human Reproduction, 2003
- Aniline Compounds
- Coloring Agents
- Eosine Yellowish-(YS)
Erik Blom
Fertility and Sterility, 1950
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Eosin
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q422637), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.